Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Abstract: Provided are methods of predicting a pairability of nucleotides of a plurality of RNA polynucleotides by (a) simultaneously determining a paired state or an unpaired state of nucleotides of the plurality of RNA polynucleotides; and (b) corresponding the paired state or the unpaired state of the nucleotides to a database of nucleic acid sequences, the database comprises nucleic acid sequences representing the plurality of RNA polynucleotides, thereby determining the pairability of nucleotides of the plurality of RNA polynucleotides. Also provided are methods of determining a secondary structure of a plurality of RNA molecules; methods of determining if a molecule is capable of modulating a secondary structure of at least one RNA polynucleotide of a plurality of RNA polynucleotides; and methods of screening for a marker associated with a pathology.

Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing autoimmune diseases or other inflammatory diseases. In particular, the present invention provides gene expression profiles as well as novel TKI Responsive Signature(s) useful for the diagnosis, characterization, prognosis and treatment of autoimmune disease or other inflammatory diseases.

Abstract: The invention pertains to a method of treating or protecting against melanoma that comprises (a) obtaining a melanoma cell line that expresses one or more shared immunodominant melanoma antigens, (b) modifying the melanoma cell line to render it capable of producing an increased level of a cytokine relative to the unmodified cell line, and (c) administering the melanoma cell line to a mammalian host that has melanoma or is at risk for developing melanoma. Preferably the melanoma cell line is allogeneic and is not MHC-matched to the host.